Replimune Group Q3 EPS Forecast Decreased by Leerink Partnrs

Replimune Group, Inc. (NASDAQ:REPL) – Leerink Partnrs lowered their Q3 2025 earnings estimates for Replimune Group in a report issued on Tuesday, November 12th. Leerink Partnrs analyst J. Chang now forecasts that the company will earn ($0.71) per share for the quarter, down from their previous estimate of ($0.64). The consensus estimate for Replimune Group’s current full-year earnings is ($3.05) per share. Leerink Partnrs also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.82) EPS and FY2026 earnings at ($2.25) EPS.

Several other equities research analysts also recently weighed in on REPL. HC Wainwright restated a “buy” rating and set a $17.00 price target on shares of Replimune Group in a report on Tuesday, November 12th. JPMorgan Chase & Co. upped their target price on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 24th. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Finally, Roth Mkm assumed coverage on shares of Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $16.80.

Replimune Group Stock Down 5.3 %

Shares of NASDAQ REPL opened at $10.80 on Friday. The stock has a market cap of $738.94 million, a P/E ratio of -3.54 and a beta of 1.19. The business’s fifty day simple moving average is $11.46 and its 200-day simple moving average is $9.57. Replimune Group has a 12-month low of $4.92 and a 12-month high of $12.97. The company has a current ratio of 10.11, a quick ratio of 13.46 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last released its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07.

Institutional Investors Weigh In On Replimune Group

Hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new position in Replimune Group in the first quarter valued at approximately $147,000. Russell Investments Group Ltd. acquired a new position in shares of Replimune Group in the 1st quarter valued at $140,000. Entropy Technologies LP boosted its holdings in shares of Replimune Group by 18.3% in the 1st quarter. Entropy Technologies LP now owns 59,326 shares of the company’s stock valued at $485,000 after buying an additional 9,180 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Replimune Group by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock valued at $22,634,000 after buying an additional 32,555 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in Replimune Group during the 1st quarter worth $927,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.